Jim Cramer's Stop Trading: The Go-To Medical Marijuana Stock

NEW YORK (TheStreet) -- On CNBC's "Cramer's Stop Trading" segment, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, pointed to the American Academy of Neurology's recent study that paints medical marijuana in positive light. 

The findings showed benefits mainly for patients with multiple sclerosis. He suggested medical marijuana has been found to help in other areas as well, including pain, epilepsy and cancer. 

And although the U.S. is slowly recognizing the benefits of marijuana for medicinal purposes, investors are curious as to which stock is in the best position to take advantage. 

Cramer suggests GW Pharmaceuticals (GWPH) as the go-to stock for investors. The company makes the cannabinoid medicine Sativex, which is marketed for the treatment of spasticity in multiple sclerosis patients. 

"I really believe" in GW Pharmaceuticals, he said, adding that the U.K.-based company will have an easier time with marijuana testing since it is in England, rather than the U.S. 

The stock is "still down a lot from its high," and this company will solve a lot of pain issues, Cramer concluded.

-- Written by Bret Kenwell in Petoskey, Mich.

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

More from Opinion

AAP Exclusive: Cramer Says The President is No Longer on the Side of the Bulls

AAP Exclusive: Cramer Says The President is No Longer on the Side of the Bulls

Why It Makes Perfect Sense for Netflix and Amazon to Buy Up Movie Theaters

Why It Makes Perfect Sense for Netflix and Amazon to Buy Up Movie Theaters

2 More Reasons to Sell All Your Stocks and Run Away

2 More Reasons to Sell All Your Stocks and Run Away

Sean Hannity's Link to Trump Lawyer Raises Questions: Doug Kass Insider

Sean Hannity's Link to Trump Lawyer Raises Questions: Doug Kass Insider

Netflix Blowout Earnings Remind Investors of One Thing: This Company Is a Beast

Netflix Blowout Earnings Remind Investors of One Thing: This Company Is a Beast